Literature DB >> 24442401

Pharmacological treatment of acromegaly: its place in the overall therapeutic approach.

Evgenia Korytnaya1, Ariel Barkan.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24442401     DOI： 10.1007/s11060-013-1353-6

Source DB:  PubMed          Journal:  J Neurooncol        ISSN： 0167-594X            Impact factor:   4.130


× No keyword cloud information.
  47 in total

1.  Variation in GH and IGF-I assays limits the applicability of international consensus criteria to local practice.

Authors:  A Pokrajac; G Wark; A R Ellis; J Wear; G E Wieringa; P J Trainer
Journal:  Clin Endocrinol (Oxf)       Date:  2007-04-15       Impact factor: 3.478

2.  Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist.

Authors:  A J van der Lely; R K Hutson; P J Trainer; G M Besser; A L Barkan; L Katznelson; A Klibanski; V Herman-Bonert; S Melmed; M L Vance; P U Freda; P M Stewart; K E Friend; D R Clemmons; G Johannsson; S Stavrou; D M Cook; L S Phillips; C J Strasburger; S Hackett; K A Zib; R J Davis; J A Scarlett; M O Thorner
Journal:  Lancet       Date:  2001-11-24       Impact factor: 79.321

3.  Preoperative lanreotide treatment improves outcome in patients with acromegaly resulting from invasive pituitary macroadenoma.

Authors:  Z-Q Li; Z Quan; H-L Tian; M Cheng
Journal:  J Int Med Res       Date:  2012       Impact factor: 1.671

4.  Comparison of the effects of primary somatostatin analogue therapy and pituitary adenomectomy on survival in patients with acromegaly: a retrospective cohort study.

Authors:  Fausto Bogazzi; Annamaria Colao; Giuseppe Rossi; Martina Lombardi; Claudio Urbani; Chiara Sardella; Aldo Iannelli; Ilaria Scattina; Luca Manetti; Simone Del Sarto; Rosario Pivonello; Ludovica Francesca Stella Grasso; Isabella Lupi; Renata Simona Auriemma; Gaetano Lombardi; Enio Martino
Journal:  Eur J Endocrinol       Date:  2013-08-28       Impact factor: 6.664

5.  The long-term efficacy of conventional radiotherapy in patients with GH-secreting pituitary adenomas.

Authors:  Giuseppe Minniti; Marie-Lise Jaffrain-Rea; Mattia Osti; Vincenzo Esposito; Antonio Santoro; Francesca Solda; Patrizia Gargiulo; Guido Tamburrano; Riccardo Maurizi Enrici
Journal:  Clin Endocrinol (Oxf)       Date:  2005-02       Impact factor: 3.478

Review 6.  Place of cabergoline in acromegaly: a meta-analysis.

Authors:  Laure Sandret; Patrick Maison; Philippe Chanson
Journal:  J Clin Endocrinol Metab       Date:  2011-02-16       Impact factor: 5.958

7.  Glucose homeostasis and safety in patients with acromegaly converted from long-acting octreotide to pegvisomant.

Authors:  Ariel L Barkan; Pia Burman; David R Clemmons; William M Drake; Robert F Gagel; Philip E Harris; Peter J Trainer; Aart Jan van der Lely; Mary Lee Vance
Journal:  J Clin Endocrinol Metab       Date:  2005-08-02       Impact factor: 5.958

8.  Estroprogestinic pill normalizes IGF-I levels in acromegalic women.

Authors:  R Cozzi; M Barausse; S Lodrini; G Lasio; R Attanasio
Journal:  J Endocrinol Invest       Date:  2003-04       Impact factor: 4.256

Review 9.  Guidelines for acromegaly management: an update.

Authors:  S Melmed; A Colao; A Barkan; M Molitch; A B Grossman; D Kleinberg; D Clemmons; P Chanson; E Laws; J Schlechte; M L Vance; K Ho; A Giustina
Journal:  J Clin Endocrinol Metab       Date:  2009-02-10       Impact factor: 5.958

10.  Acromegaly: correlation between expression of somatostatin receptor subtypes and response to octreotide-lar treatment.

Authors:  Ana Paula M Casarini; Raquel S Jallad; Emília M Pinto; Iberê C Soares; Suely Nonogaki; Daniel Giannella-Neto; Nina R Musolino; Venâncio A F Alves; Marcello D Bronstein
Journal:  Pituitary       Date:  2009       Impact factor: 4.107
View more
  1 in total

Review 1.  New therapeutic agents for acromegaly.

Authors:  Shlomo Melmed
Journal:  Nat Rev Endocrinol       Date:  2015-11-27       Impact factor: 43.330
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.